Losartan inhibited expression of matrix metalloproteinases in rat atherosclerotic lesions and angiotensin II-stimulated macrophages.

AIM To explore whether the angiotensin II (Ang II) receptor 1 (AT1) antagonist, losartan could reduce activity and expression of matrix metalloproteinases (MMPs) in rat atherosclerotic plaques. METHODS Male Wistar-Kyoto rats were ip injected a single dose of vitamin D3 600 kU x kg(-1) x month(-1) and fed an atherogenic diet for 4 months to induce experimental atheroma. Then either placebo or losartan 50 mg x kg(-1) x d(-1) was administered in rats for another 2 months. In vitro, the effect of losartan 0.1-10 micromol/L on the expression of MMP-2 and MMP-9 was investigated in Ang II-stimulated rat peritoneal macrophages. The expression and activity of MMP-2 and MMP-9 were monitored by Western blot, RT-PCR, and SDS-PAGE zymography analysis. RESULTS High levels of MMP-2 and MMP-9 were expressed in rat atherosclerotic lesions. Losartan significantly reduced the activity and expression of MMP-2 and MMP-9 compared with the placebo group (MMP-2, 5861+/-539 vs 8991+/-965, P<0.05; MMP-9,10527+/-1002 vs 14623+/-2462, P<0.01). In cultured rat peritoneal macrophages, Ang II 0.1 micromol/L elicited an increase in MMP-2 and MMP-9 activity and expression that were prevented by losartan in a dose-dependent manner (P<0.01). But the AT2 receptor antagonist PD123319 had no effect. CONCLUSION Losartan reduced the expression and activity of MMP-2 and MMP-9 in rat atherosclerotic lesions. The anti-atherogenic effects of losartan were due to the direct inhibition of Ang II bioactivity.

[1]  J. Mehta,et al.  Modulation of Matrix Metalloproteinase-1, Its Tissue Inhibitor, and Nuclear Factor-&kgr;B by Losartan in Hypercholesterolemic Rabbits , 2002, Journal of cardiovascular pharmacology.

[2]  A. Newby,et al.  Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. , 2001, Cardiovascular research.

[3]  J. Egido,et al.  Angiotensin II activates nuclear transcription factor-kappaB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  S. Parthasarathy,et al.  Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. , 2001, Journal of the American College of Cardiology.

[5]  I. Dixon,et al.  Effect of chronic AT(1) receptor blockade on cardiac Smad overexpression in hereditary cardiomyopathic hamsters. , 2000, Cardiovascular research.

[6]  C. Ferrario,et al.  Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. , 2000, Circulation.

[7]  T. Yu,et al.  Effects of angiotensin-converting enzyme and angiotensin II on hypoxia-induced proliferation of cultured intra-pulmonary artery smooth muscle cells. , 2000, Acta pharmacologica Sinica.

[8]  H. Drexler,et al.  Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. , 2000, Circulation.

[9]  A. Takeshita,et al.  Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. , 2000, Circulation.

[10]  N. Hirose,et al.  Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. , 1999, Atherosclerosis.

[11]  S. Kaul,et al.  Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. , 1999, Circulation.

[12]  U. Nannmark,et al.  Matrix metalloproteinases produced by rat IL-2-activated NK cells. , 1998, Journal of immunology.

[13]  G. Callis,et al.  Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Breslow,et al.  The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. , 1997, Biochemical and biophysical research communications.

[15]  G. Berry,et al.  Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. , 1996, Circulation.

[16]  J. Isner,et al.  Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. , 1995, Circulation.

[17]  J. S. Janicki,et al.  Prevention of angiotensin II induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat. , 1995, Cardiovascular research.

[18]  T. Kitazono,et al.  Evidence that angiotensin II is present in human monocytes. , 1995, Circulation.

[19]  G. Tsujimoto,et al.  Modulation of angiotensin II type 1 receptor mRNA expression in human blood cells: comparison of platelets and mononuclear leucocytes. , 1995, Endocrine journal.

[20]  Y. Yamaguchi,et al.  Release of endogenous ATP from the caudal artery in rats with arteriosclerosis. , 1994, European journal of pharmacology.

[21]  V. Fuster,et al.  Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture , 1994, Circulation.

[22]  E. H. Blaine,et al.  Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. , 1993, The Journal of clinical investigation.

[23]  R D Kamm,et al.  Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. , 1992, Circulation research.

[24]  A. Chobanian,et al.  Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. , 1992, Hypertension.

[25]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[26]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[27]  G. Åberg,et al.  Effects of Captopril on Atherosclerosis in Cynomolgus Monkeys , 1990, Journal of cardiovascular pharmacology.

[28]  J. Weinstock,et al.  Angiotensin II is chemotactic for a T-cell subset which can express migration inhibition factor activity in murine schistosomiasis mansoni. , 1987, Cellular immunology.

[29]  A. Becker,et al.  Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. , 1994, Circulation.